Given the advancements in treatment, viral breakthrough
is not uncommon.
Even within genotype 1, patients with subtype la infections have experienced a higher rate of drug resistance and viral breakthrough
than subtype lb.
There were no cases of viral breakthrough
during therapy, and HCV deep se-quencing in a subgroup of patients detected none of the genetic mutations known to be associated with resistance to sofosbuvir.
The cerebral vasoconstriction was associated with treatment intensification with peginterferon alfa and ribavirin following viral breakthrough
in one patient.
All patients receiving 4 weeks of treatment with ACH-1625 demonstrated continuous and substantial declines in HCV RNA with no viral breakthrough
during therapy at any of the doses.
Both viral breakthrough
and genotypic resistance were significantly less common with telbivudine.
The secondary endpoint of combination therapy was prevention of viral breakthrough
and emergence of resistant-type HBV.
This patient had a partial response to treatment but developed viral breakthrough
and was discontinued.
No patients dropped out of the study because of drug-related events, and no cases of viral breakthrough
or post-treatment relapse have been reported to date, Dr.
The study also found that in a GT1a prior null responder population, an interferon-free regimen of DCV, ASV 200 mg BID and ribavirin resulted in a high rate of viral breakthrough
and did not warrant further investigation.
The Hemopurifier is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough
during standard-of-care therapy.
rates during treatment were highest in the telaprevir/interferon-only group, at 21%, compared with 11%, 10%, and 3% in the T12/ PR24, T24/PR48, and PR48 groups.